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Abstract
Background
Growth arrest-specific gene 6 (Gas6), a vitamin K-dependent protein interacting with
anionic phospholipids and TAM tyrosine kinase receptors, is elevated in plasma of septic
patients. Previous studies did not find different levels between survivors and non-survivors
at admission because either they included a low number of patients (<50) or a low number
of non-survivors (5%).
Objectives
To determine, in a larger cohort of septic patients comprising an expected number of non-
survivors, the performance of the plasma level of Gas6 and its soluble receptor Axl (sAxl)
within 24 hours of admission to predict in-ICU mortality.
Patients
Septic adults with or without shock.
Methods
Gas6 and sAxl were prospectively measured by ELISA at day 0, 3, 7, and then weekly until
discharge or death.
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Results
We evaluated 129 septic patients, including 82 with and 47 without shock, with in-ICU mor-
tality rate of 19.4% and in-hospital mortality rate of 26%. Gas6 level was higher in non-survi-
vors than in survivors (238 vs. 167%, P = 0.003); this difference remained constant during
the ICU stay. The area under the ROC curve for Gas6 (0.695 [95% CI: 0.58–0.81]) was
higher than for sAxl, procalcitonin, CRP, IL-1beta, IL-6 and-alpha, and slightly higher than
for IL-8, IL-10, SOFA and APACHEII scores in predicting in-ICU mortality. Considering
249% as a cut-off value, Gas6 measurement had a negative predictive value for mortality of
87%.
Conclusion
It seems that Gas6 plasma level within 24 hours of ICU admission may predicts in-ICU mor-
tality in patients with sepsis. If our result are confirmed in external validation, Gas6 plasma
level measurement could contribute to the identification of patients who may benefit most
from more aggressive management.
Introduction
Sepsis is the leading cause of mortality in the intensive care unit (ICU) [1]. Despite significant
improvement in clinical management, mortality rate still reaches almost 30% [2]. These last
years, important efforts have been performed to identify and describe biomarkers that could be
used to assist physicians in risk stratification and decision-makingprocesses [3]. For example,
the level of blood C-reactive protein (CRP), cytokines, procalcitonin (PCT) and lipopolysac-
charide (LPS)-binding protein are elevated in sepsis. However, insufficient sensitivity and spec-
ificity of these measurements prevent currently their use for early diagnosis of sepsis and
management [3–5]. We recently confirmed the prognostic value of pancreatic stone protein to
predict, in combination with severity scores, the outcome of patients with sepsis requiring ICU
management [6,7]. However, it is necessary to identify novel sepsis biomarkers [5,8].
Growth arrest-specific gene 6 (GAS6) was first described in fibroblast during growth arrest
[9]. It encodes Gas6, a secreted vitamin K-dependent protein expressed mainly in endothelial
[10], vascular smooth muscle [11], bone marrow [12] and central nervous system cells [13].
Gas6 amino acid sequence shares 44% homology with that of protein S (PS) [10], a coagulation
regulatory protein which acts as cofactor for both activated protein C and tissue factor pathway
inhibitor [14, 15]. Gas6 is composed of four domains: a Gla domain, which requires gamma-
carboxylation to be functional and interacts with membrane phospholipids, four EGF-like
domains and a sex-hormone-binding globulin domain which comprises the binding site for
receptors of the TAM (Tyro3, Axl and Mer) family [16]. TAM are tyrosine kinase receptors
exhibiting a widespread expression distribution, including immune cells such as macrophages
and dendritic cells [17]. TAM activation participates in a number of pathophysiological events
linked to sepsis like phagocytosis, cytokine production and antigen-presentation [18,19].
Gas6 and its receptors are regulators of innate immunity, promoting anti-inflammatory
responses through inhibition of cytokine production by antigen-presenting cells [20]. Gas6 is
implicated in coagulation and platelets function, participating to platelet adhesion to endothe-
lium as well as to thrombus stabilization [21–24]. Apoptotic cell phagocytosis is predominantly
driven via Mer in a homeostatic environment and via Axl in an inflammatory environment
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[25]. Exposure of macrophages to LPS promotes the cleavage of Axl and Mer into soluble
forms, which interact with Gas6 and diminish the effectiveness of apoptotic cell phagocytosis
[26,27]. Toll-like Receptor activation reduces the production of Gas6 and PS which in turn
facilitates pro-inflammatory cytokine production by macrophages [28]. Recent studies indicate
that Gas6 influences host responses to endotoxemia and bacterial infection by modulating
innate immunity and may have thereby a protective role during sepsis [20]. Furthermore, the
administration of Gas6 to wild type mice with cecal ligation and puncture reduces circulating
levels of IL-6 and IL-17 [29].
Plasma Gas6 levels are elevated in humans with inflammatory conditions, including sepsis
[30] and correlate with organ dysfunction and disease severity [31]. Yet Gas6 plasma level at
admission did not discriminate between survivors and non-survivors [30–33]. However, it
should be emphasized that these studies included either few septic patients (<50) [31–33] or
few non-survivors (5%) [30].
Here, in a cohort of 129 septic patients with an in-hospital mortality ranging from 20.5 to
37% [6,7] as expected in Europe [34], we investigated prospectively the performance of Gas6
plasma level at admission to predict the risk of mortality.
Materials and Methods
Patients
The study was performed between February 2008 and July 2012 in a 32-bed adult medico-sur-
gical ICU of a community and referral university hospital. Patients who were at least 18 years
old were evaluated within 24 hours of ICU admission for sepsis with or without shock. Infec-
tions, sepsis and septic shock were defined according to commonly used criteria [35]. As Gas6
is a modulator of innate immunity, exclusion criteria were HIV-positive status, hematological
malignancies, immunosuppressive treatment and agranulocytosis.Owing to organizational
constraints, inclusion was prospective but could not be strictly consecutive. Patients were fol-
lowed until death or discharged from the ICU. In-ICUmortality was the primary endpoint.
The study was approved by the Institutional ReviewBoard (Commission cantonale [VD]
d’éthique de la recherche sur l’être humain, Lausanne, Switzerland).Written informed consent
was obtained from patients or relatives.
Data collection and blood sampling
Data collectionwas performed as previously described [6,7]. Severity of the illness was evalu-
ated on the first day in the ICU by using the Acute Physiology and Chronic Health Evaluation
II (APACHE II) score [36]. Organ dysfunctionwas evaluated by the Sequential Organ Failure
Assessment (SOFA) score [37]. McCabe classification was recorded for each patient [38].
Citrated bloodwas collected at admission (Day 0), Day 3, Day 7 and then weekly until dis-
charge from ICU or death and plasma samples were stored at -80°C until use.
Gas6 and sAxl ELISA
To measure Gas6, we used the ELISAmethod developed by Clauser et al [39] with some modi-
fications as reported below in order to globally reduce the amount of antibodies. Sensibility
and specificity of the modifiedmethod were however comparable to those of the original
method [39]. Wells from 96-wells plates (Maxisorp, Nunc) were coated with 50 μL per well of
5 μg/mL polyclonal goat anti-human Gas6 antibody (AB885, R&D Systems, Abingdon, United
Kingdom) diluted in 0.1MNaHCO3 pH 8.2 and incubated overnight at 4°C. After two washes
with PBS-Tween 0.05%, 200 μL PBS-BSA 1% were added to the wells and plates were incubated
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2 hours at room temperature. After three washes, samples and normal plasma serial dilution
with PBS-BSA 1% were added to the wells, followed by two hours incubation at RT. After three
washes, 50 μL of 0.25 ug/mL biotinylated polyclonal goat antibody (BAF885, R&D Systems,
Abingdon, United Kingdom) were added to each well, and plates left two hours at room tem-
perature. Signal was amplified with Avidin-horseradisch-peroxidase (BD Pharmingen, Oxford,
United Kingdom) and plates incubated during 30 minutes at RT. Finally, SureBlue Reserve
TMB (KPL, Gaithersburg, United States of America) was added. Reactions were stopped by
adding 100 μL HCl 1M. Absorbance was measured at 450 nm and results were expressed in
percentage relative to normal plasma, using its serial dilution as standard curve. This ELISA
was specific for human Gas6, with no cross-reactivity with human PS. Gas6 plasma level was
measured in all patients at admission (Day 0), Day 3, Day 7 and the weekly until discharge
from ICU or death. We used a commercial kit from R&D Systems (DY154, Abingdon, United
Kingdom) to measure sAxl, following the instruction provided by the manufacturer. sAxl
plasma level was expressed in ng/mL and measured in all patients only at admission (Day 0).
Measurement of plasma levels of other circulating biomarkers
Other circulating biomarkers like CRP, PCT, and cytokines were measured on Day 0, as previ-
ously described [7].
Statistical analysis
Gas6 and sAxl levels between survivors and non-survivors and between septic patients with
sepsis and without shock were compared with the two-sample Wilcoxon-Mann-Whitney rank
sum test and differences among proportions derived from categorical data were compared
using the Fisher exact test. APACHE II and SOFA scores, CRP and PCT are expressed as
median and range.
To study if Gas6 or sAxl level at admission predicted the ICU-mortality, we used Cox
regression models in which Gas6 or sAxl were entered as continuous variables. We performed
only an univariate analysis because the number of patients by subgroups was too small to real-
ize a multivariate analysis.
A cut-off of plasma Gas6 concentration (249%) was defined as the value with the maximum
of specificity and sensitivity to discriminate between survivors and non-survivors. A further
analysis compared survival in patients having 249% vs. those having<249% Gas6 level. Log-
rank test was used to compare the two groups.
To compare Gas6 evolution over time in deceased vs. surviving patients, we used linear
mixedmodels, with random constants. We estimated the effect of survival, time and the inter-
action between time and survival on Gas6.
The association betweenGas6 and the other variables measured was assessed with Spear-
man correlation coefficients.
Receiver operating characteristic (ROC) curvewas applied to examine the performance of
variables to predict intra-ICUmortality.
All P values were two-sided and considered statistically significant if the P value was less
than or equal to 0.05.
Statistical analyses and graphics were performed using the statistical packages STATA (Sta-
taCorp LP, College Station, Texas, United States of America) and Prism Graphpad (Graphpad
Software, La Jolla, California, United States of America).
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Results
Patient characteristics
A total of 273 patients were prospectively screened (Fig 1); of these, 113 (41%) were excluded
(54 declined consent, 22 died before consent could be obtained, 14 were transferred to another
hospital before being enrolled, 4 had no discernment capacity, 15 were lost to follow up because
of transfer to another hospital or failure to collect blood samples or clinical data, 2 had no
infection, 1 spoke Russian and 1 did not have blood draw for technical reasons). From the 160
enrolled in the cohort, 5 were excluded because of HIV status, 10 because of hematological
malignancy, 10 because of immunosuppression, 6 because of agranulocytosis.
A total of 129 patients were included in the study. Patients’ characteristics and clinical
parameters are listed in Table 1. There was a male predominance (61.2%) and a median age of
66 years (range 18–85). We reported 47 cases of sepsis without shock (36.4%) and 82 of sepsis
with shock (63.6%). Ninety-three (72.1%) infections were community-acquired, 28 (21.7%)
nosocomial and 8 (6.2%) health-care associated. The three main diagnoses at admission in the
ICU were pneumonia (38.8%), peritonitis (24.8%) and fasciitis (10.1%) and the most common
pathogens isolated from patients were E. coli (19.4%), S. pneumoniae (17.1%), S. pyogenes (7%).
In 21.7% of the cases no pathogen was identified.
With respect to patient co-morbidities, 20.2% had diabetes but only a quarter of them
required insulin, 15.5% suffered from COPD and 17.1% had coronary artery disease. The in-
ICUmortality represented 19.4%, the 28-day mortality 22%, the in-hospital mortality 26% of
the cohort's population. The vast majority of non-survivors suffered from septic shock (23 out
of 25).
The severity scores used were APACHE II with median value of 28 points (range 13–46)
and SOFA with median value of 11 points (range 5–20). Ten percent had McCabe classification
predicting rapidly fatal outcome. The median value for CRP was 257 mg/L (range 4–558) and
for PCT 21.4 μg/L (range 0.1–201). Age (P<0.001), septic shock (P = 0.001), APACHE II score
(P = 0.004) and SOFA score (P = 0.010) were higher in non-survivors.McCabe classification
was higher in survivors (P = 0.042). The etiological agent, the final diagnosis, CRP and PCT
levels and the presence of diabetes, COPD or coronary artery disease were not statistically dif-
ferent between survivors and non-survivors.
Fig 1. Flow diagram of patients included in the study.
doi:10.1371/journal.pone.0163542.g001
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Table 1. Patient characteristics by survival status.
Patient characteristic All Patients (n = 129) Survivors (n = 104) Non-survivors (n = 25) P-value
Age, median years (range) 66 (18–85) 63 (18–85) 75 (55–85) <0.0011
Sex, male 79 65 (62.5%) 14 (56.0%) 0.6492
Sepsis without shock 47 45 (43.3%) 2 (8.0%) 0.0012
Septic shock 82 59 (56.7%) 23 (92.0%) 0.0012
Cause of sepsis with/without shock 0.7842
Pneumonia 50 38 (36.5%) 12 (48.0%)
Peritonitis 32 26 (25.0%) 6 (24.0%)
Fasciitis 13 12 (11.5%) 1 (4.0%)
Cholangitis 6 4 (3.8%) 2 (8.0%)
Pyelonephritis 9 7 (6.7%) 2 (8.0%)
Primary bacteremia 3 3 (2.9%) 0 (0.0%)
Meningitis 4 4(3.8%) 0 (0.0%)
Abscess 2 2 (1.9%) 0 (0.0%)
Endocarditis 4 3 (2.9%) 1 (4.0%)
Others 6 5 (4.8%) 1 (4.0%)
Pathogens 0.7112
E. coli 25 21 (20.2%) 4 (16.0%)
S. pneumoniae 22 18 (17.3%) 4 (16.0%)
S. pyogenes 9 8 (7.7%) 1 (4.0%)
P. aeruginosa 7 6 (5.8%) 1 (4.0%)
S. aureus (MRSA) 9 (1) 7 (1) (6.7%) 2 (0) (8.0%)
Other pathogen isolated 29 25 (24.0%) 4 (16.0%)
No pathogen identified 28 19 (18.3%) 9 (36.0%)
Origin 0.2142
Community-acquired 93 76 (73.1%) 17 (68.0%)
Nosocomial 28 20 (19.2%) 8 (32.0%)
Health-care associated 8 8 (7.7%) 0
Comorbidities
Diabetes (with insulin therapy) 26 (7) 20 (6) (19.2%) 6 (1) (24.0%) 0.5862
COPD 20 16 (15.4%) 4 (16.0.6%) 1.0002
Coronary artery disease 22 19 (18.3%) 3 (12.0%) 0.5652
McCabe classification 0.0422
Non-fatal 77 67 (64.4%) 10 (40%)
Ultimately fatal (< 5 years) 39 29 (27.9%) 10 (40%)
Rapidly fatal (< 6 months) 13 8 (7.7%) 5 (20%)
APACHE II, median (range) 28 (13–46) 27 (13–46) 33 (22–45) 0.0041
SOFA, median (range) 11 (5–20) 10 (5–20) 13 (6–19) 0.0101
CRP, median (range) 257 (4–558) 262 (4–558) 225 (70–538) 0.3831
PCT, median (range) 21.4 (0.1–201) 21.3 (0.1–201) 24.6 (1.7–201) 0.3281
1 Mann-Whitney test.
2 Fisher’s exact test.
APACHE II = Acute Physiology and Chronic Health Evaluation II, COPD = Chronic Obstructive Pulmonary Disease, CRP = C-reactive protein,
MRSA = methicillin resistant S. aureus, PCT = Procalcitonin, SOFA = Sequential Organ Failure Assessment.
doi:10.1371/journal.pone.0163542.t001
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Plasma levels of Gas6 and sAxl
Median plasma Gas6 and sAxl levels at admission were comparable in septic patients with and
without shock (Fig 2A and 2B, P> 0.05). There were no significant differences of Gas6 and
sAxl levels between bacteriemic and non-bacteriemic patients and betweenGram-negative and
Gram-positive infections.
However, Gas6 levels at admission were higher in non-survivors (median 238%, IQR 217)
than in survivors (median 167%, IQR 106) (Fig 2C, n = 129, P = 0.003). The relative risk of
death during the ICU stay was multiplied by 1.0037 for each supplementary percentage of
plasma Gas6 level at admission (Cox regression, 95% CI: 1.0014–1.0059, P = 0.001). An aug-
mentation of 50% of Gas6 level at admission increased by 20% in the relative risk of death dur-
ing the ICU stay (Hazard Ratio: 1.20, 95% CI: 1.07–1.34%).
Similarly, non-survivors exhibited a higher sAxl plasma levels than survivors (median 34.5
ng/ml, IQR 29 vsmedian 31 ng/ml, IQR 14.5 respectively), but this was not statistically signifi-
cant (P = 0.163, Fig 2D).
The linear mixedmodel to study Gas6 evolution during the ICU stay demonstrated that the
interaction between survival and time was not statistically significant. This analysis suggests
that difference in Gas6 level between survivors and non-survivors remained constant over
time. Independently from time, non-survivors had a mean level of Gas6 83% higher than survi-
vors. We therefore proposed a secondmodel that excludes the time-survival interaction (Fig
3). According to this last model, non-survivors exhibited a mean Gas6 level of 262% versus
179% in survivors at admission (P for the difference<0.001). Gas6 then decreased by 1.36%
(P = 0.010) each day in both groups. Whatever model we used, the Gas6 curve remained more
elevated in non-survivors than in survivors.
As the number of non-survivors diminished rapidly after D0, we focused our next analysis
on results from the first blood sample.
Fig 2. Gas6 and soluble Axl (sAxl) levels. (A) Gas6 plasma levels at admission in septic patients with
shock (median 180.5, IQR 130) and without shock (median 173, IQR 104) (P > 0.05, Wilcoxon rank-sum
(Mann-Whitney) test), (B) sAxl plasma levels at admission in septic patients with shock (median 35, IQR
20.5) and septic patients without shock (median 31, IQR 13) (P > 0.05, Wilcoxon rank-sum (Mann-Whitney)
test), (C) Gas6 plasma levels at admission in survivors (median 167%, IQR 106) and non-survivors (median
238%, IQR 217) (P = 0.003, Wilcoxon rank-sum (Mann-Whitney) test), (D) sAxl plasma levels at admission in
survivors (median 31, IQR 14.5) and non-survivors (median 34.5, IQR 29) (P > 0.05, Wilcoxon rank-sum
(Mann-Whitney) test).
doi:10.1371/journal.pone.0163542.g002
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Correlation of Gas6 with biomarkers of inflammation and severity scores
Gas6 levels at admission correlated positively with plasma levels of IL-6, IL-8, IL-10 and sAxl.
Correlation with IL-1beta and TNF-alpha was not significant. PCT correlated with Gas6, while
CRP, SOFA and APACHEII scores did not (Table 2).
Biomarkers and severity scores as predictors of intra-ICU mortality
Except Gas6, the only biomarkers found to be differently expressed between survivors and
non-survivors were IL-8 (P = 0.003) and IL-10 (P = 0.004). Both SOFA and APACHE II scores
predictedmortality during ICU stay (P = 0.011 and 0.004, respectively).
Table 3 shows the area under the curve (AUC) of the different markers and Fig 4 illustrates
the ROC curves of the blood parameters and clinical scores which are statistically different
between survivors and non-survivors. Based on the ROC curve area, Gas6 has, albeit modestly,
the highest diagnostic efficacy of intra-ICUmortality.
Considering 249% as a cut-off value, which was result driven, Gas6 measurement had a
specificity of 82.7% (95% CI: 74%-89%) and a sensitivity of 48% (95% CI: 28%-69%) with a
positive likelihood ratio of 2.77 for predictingmortality. Positive and negative predictive values
Fig 3. Evolution of Gas6 levels during ICU stay. The scheme is based on a linear mixed model without
interaction between time in ICU and survival. Round represent the observed measures in survivors (a) and
non-survivors (b), respectively. Lines represent the model-fitted values.
doi:10.1371/journal.pone.0163542.g003
Table 2. Correlation between the plasma levels of Gas6 and those of other biomarkers.
Biomarker rho P
sAxl 0.33 <0.001
IL-10 0.31 <0.001
IL-8 0.31 <0.001
IL-6 0.26 0.004
PCT 0.23 0.009
TNF-alpha 0.14 0.113
SOFA 0.11 0.212
IL-1 0.06 0.507
APACHE II 0.04 0.212
CRP -0.10 0.270
APACHE II = Acute Physiology and Chronic Health Evaluation II, CRP = C-reactive protein, IL = Interleukin,
PCT = Procalcitonin, SOFA = Sequential Organ Failure Assessment, TNF = Tumor necrosis factor.
doi:10.1371/journal.pone.0163542.t002
Early Elevated Gas6 as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis
PLOS ONE | DOI:10.1371/journal.pone.0163542 October 27, 2016 8 / 13
for mortality were 40% and 87%, respectively. A log-rank test showed that there was a signifi-
cant difference (P = 0.026) between survival curves in the two groups (Fig 5).
Discussion
Our data suggest that Gas6, measured within 24 hours of ICU admission, may help to predict
the risk of mortality in septic patients with and without shock. Previous work showed that high
plasma Gas6 level correlates with the degree of organ dysfunction. Endogenous Gas6 has a
Table 3. Performance of different biomarkers to predict mortality based on ROC curve area.
Biomarker ROC area SE 95%CI
Gas6 0.695 0.061 0.576–0.814
IL-8 0.693 0.056 0.584–0.803
IL-10 0.688 0.052 0.586–0.790
APACHE II 0.686 0.052 0.584–0.788
SOFA 0.664 0.063 0.540–0.788
TNF-alpha 0.624 0.059 0.509–0.739
IL-6 0.623 0.064 0.498–0.748
sAxl 0.592 0.069 0.458–0.727
IL-1beta 0.570 0.071 0.431–0.708
PCT 0.563 0.058 0.449–0.677
CRP 0.556 0.062 0.434–0.678
SE = Standard Error, 95% CI = 95% Confidence Interval, APACHE II = Acute Physiology and Chronic Health
Evaluation II, CRP = C-reactive protein, IL = Interleukin, PCT = Procalcitonin, SOFA = Sequential Organ
Failure Assessment, TNF = Tumor necrosis factor.
doi:10.1371/journal.pone.0163542.t003
Fig 4. Receiver operator characteristic curve analysis of blood parameters for death in the ICU. The
value of the Area Under the Curve for each blood parameter and the 95% confidence intervals are listed on
the bottom right of the figure. APACHE II = Acute Physiology and Chronic Health Evaluation II,
IL = Interleukin, SOFA = Sequential Organ Failure Assessment.
doi:10.1371/journal.pone.0163542.g004
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homeostatic role by acting on macrophages and plays a beneficial role in murine models of
endotoxemia [29]. Gas6 attenuates the systemic inflammatory response in the early phase of
sepsis. Recently, it has been shown that recombinant Gas6 rescuesmice frommortality follow-
ing cecal ligation and puncture and reduces both plasma cytokine levels and cellular infiltration
in the lungs [29]. However, Gas6 might also contribute to the hypo-inflammatory response in
a later phase of sepsis and participate to a compensatory anti-inflammatory response syndrome
that might results in immunoparalysis with inability to clear the original pathogen invasion or
predisposes to secondary infection [40].
The present study proposes that Gas6, measured within 24 hours of ICU admission, may be
used as a biomarker to identify septic patients at highest risk of death. Nevertheless, Gas6 level
was not different between septic patients with or without shock. The strength of the present
study is that included patients are representative of the population usually admitted to a med-
ico-surgical ICU. Clinical scores (SOFA and APACHEII) predictedmortality during ICU stay.
BecauseGas6 is a modulator of innate immunity, patients with HIV status, hematological
malignancies, immunosuppression or agranulocytosiswere excluded. Gas6 performed better
than PCT and CRP, both broadly used to diagnose infection but, because of their poor accuracy
in this specific indication, should not be used to predict disease outcome. A major difference
betweenGas6 and currently used predictors of sepsis evolution, such as cytokines, is the
absence of time-survival interaction. Indeed, Gas6 level remained more elevated in non-survi-
vors than in survivors during the 28-day observation time. Although Gas6 level slightly
decreased each day both in survivors and non-survivors, this diminution was not statistically
significant. This biomarker behavior contrasts with that of pro-inflammatory cytokines like
TNF-alpha, IL-1, IL-6, which are characterized by their transient increase in plasma, rendering
the interpretation of their plasma level difficult in patients in whom the time between the onset
of sepsis and the blood draw cannot be standardized [41]. On contrary, because Gas6 level did
not follow a significant time course, it would not be a suitable biomarker to appreciate the
patient’s response to therapy. Finally, considering Gas6 plasma level of 249% as a cut-off value,
Gas6 measurement had a negative predictive value for mortality of 87%. This last findingmay
allow to identify potential survivors.
Fig 5. Survival curves of patients with sepsis with or without shock. Using Kaplan-Meier curves,
stratified by Gas6 measurement at admission with a cut-off value of 249% (relative to Gas6 concentration in
normal plasma) (P = 0.026, Log-rank test).
doi:10.1371/journal.pone.0163542.g005
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Our study has also several limitations. First, since 113 out of 273 (41%) patients were
excludedmainly because informed consent could not be obtained within 24 hours (90 patients,
33%), a selection bias cannot be excluded. Second, owing to organizational constraints, patient
recruitment was restricted to periodswhen investigators worked as attending physicians.
Third, since the present study is a cohort-based study of patients with a definite diagnosis of
sepsis at the time of ICU admission, patients without sepsis were not included. Fourth, owing
the relatively small number of patients, these results require further validation in a larger and
multi-centric cohort of patients with sepsis, which could, furthermore, allow extensive model
making.
Overall, our data suggest that plasma Gas6 level measurement could be useful to stratify
patients with sepsis. After initial resuscitation, Gas6 level determinedwithin 24 hours of ICU
admission may be used with clinical and multi-marker panel, of both pro- and anti-inflamma-
torymarkers [5,8], to select patients at high risk of death and to reduce the number of those
susceptible to receive novel and expensive adjunctive therapies.
Conclusion
We conclude that a single measurement of plasma Gas6 level within 24 hours of ICU admis-
sion stratifies septic patients with or without shock according to risk of death. If our findings
are confirmed by further studies, this promising biomarker may help critical care physicians to
tailor therapy to individual patients according to risk of death.
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